Surfactant and Use of Exogenous Surfactant in Neonatal RDS

Year 2000, Volume: 1 Issue: 2, 47 - 52, 01.08.2000

Nilgün Kültürsay Nermin Tansuğ

Abstract

Respiratory distress syndrome (RDS) and its complications are major causes of mortality and morbidity among newborns. One-fourth of newborn deaths is due to RDS in well developed countries. Besides developments in supportive treatment and use of assisted mechanical ventilation, application of surfactant replacement treatment has significantly recently decreased RDS related mortality. Fujiwara and colleagues pioneered surfactant treatment in 1980 and numerous clinical trials has been performed since then. However dose of surfactant, number of doses, dose intervals, type of surfactant, and techniques of administration has still been under investigation.

Keywords

surfactant, respiratory distress syndrome

References

• 1. Mercier CE, Soll RF. Clinical trials of natural surfactant in respiratory distress syndrome. Clin Perinatol 1993; 20: 711-35.
• 2. Corbet A. Clinical trials of synthetic surfactant in res￾piratory distress syndrome of premature infants. Clin Perinatol 1993; 20: 737-60.
• 3. Fanaroff AA, Martin RJ. The respiratory distress syn￾drome and its manegement. In: Neonatal-Perinatal Medi￾cine. Diseases of The Fetus and Infant. Ed. Fanaroff AA, Martin RJ. Fifth Edition, Msby Year Book, St Louis, Missouri, 1992: 810-20.
• 4. Neonatal Resüsitasyon Programý 2000. T.C: Saðlýk Bakanlýðý Ana Çocuk Saðlýðý ve Aile Planlamasý Genel Müdürlüðü.
• 5. Hansen T, Corbet A. Lung Development and Function. In: Avery’s Diseases of The Newborn. Ed. Taeusch HW, Ballard RA, Seventh Edition, WB Saunders Com￾pany, Philadelpia. 1998: 541-51.
• 6. Benson BJ. Genetically engineered human pulmonary surfactant. Clin Perinatol 1993; 20: 791-811.
• 7. Dekowski SA, Holtzman RB. Surfactant Replacement Therapy. The Pediatric Clinics of North America 1993; 45: 549-72.
• 8. Jobe AH, Ikegami M. Surfactant metabolism. Clin Perinatol 1993; 20: 683-96.
• 9. Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for neonatal respiratory disease in multible kindreds. J Clin Invest 1994; 93: 1860-3.
• 10. Adams FH, Fujiwara T, Emmanouilides GC, et al: Lung phospholipid of the human fetus and infants with and without hyaline membrane disease. J Pediatr 1970; 77: 833-7.
• 11. Hallman M, Merritt TA, Pohjavuori M, et al. Surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: Evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure. Pediatr Res 1986; 20:1228-34.
• 12. Jackson JC, Palmer S, Standaert TA, et al. Devolepmental changes of surface active material in newborn non-human primates. Am Rev Dis 1984; 29: 204-9.
• 13. Jobe AH. Fetal lung development, tests for matura￾tion, induction of maturation and treatment In: Mater￾nal Fetal Medicine Eds: Creasy RK, Resnik RWB. Saunders Company Philadelphia, 1989, 423-40.
• 14. Whitsett JA, Pryhuber GS, Rice WR, et al. Acute respiratory disorders. In: Neonatology Pathophysiolgy and Management of the Newborn. Ed. Avery GB, Fourth Edition, JB Lippincott Company, Philadelphia. 1994: 429-52.
• 15. Schürch S. Surface Tension Properties of Surfactant. Clin Perinatol 1993; 20: 669-82.
• 16. Couser RJ, Ferrara TB, Ebert J, et al. Effects of exog￾enous surfactant therapy on dynamic compliance dur￾ing mechanical breathing in preterm infants with hya￾line membrane disease. J Pediatr 1990: 116: 119-24.
• 17. Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1: 55-9.
• 18. Holm BA, Waring AJ. Designer surfactants. Clin Perinatol 1993; 20: 813-29.
• 19. OSÝRÝS Early versus delayed neonatal administration of a synthetic surfactant- the judgement of OSIRIS. Lancet 1992; 340: 1363-9.
• 20. Kendig JW, Ryan RM, Sinkin RA, et al. Comparison of Two Strategies for Surfactant Prophylaxis in Very Prematüre Infants: A Multicenter Randomized Trial. Pediatrics 1998; 101 : 1006-12.
• 21. Hudak ML, Martin DJ, Egan EA, et al. A Multicenter Randomized Masked Comparison Trial of Synthetic Surfactant Versus Calf Lung Surfactant Extract in the Prevention of Neonatal Respiratory Distress Syndrome. Pediatrics 1997; 100: 39-50.
• 22. Halliday HL. Synthetic or natural surfactants. Acta Paediatr 1997; 86: 233-7.
• 23. Vermont- Oxford Neonatal Network. A Multicenter, Randomized Trial Comparing Synthetic Surfactant With Modified Bovine Surfactant Extract in the Treatment of Neonatal Respiratory Distress Syndrome. Pediat￾rics 1998; 97: 1-6.
• 24. Soll Rf. Natural surfactant extract versus synthetic sur￾factant for neonatal respiratory distress syndrome. In: Cochrane Library, Issue 1, 2000. Oxford: Update Sortware.
• 25. American Academy of Pediatrics. Committee on Fetus and Newborn. Pediatrics 1999; 103: 684-5.
• 26. Murdoch E, Kempley ST. Randomized trial examining cerabral haemodynamics following artificial or animal surfactant. Acta Paediatr 1998; 87: 411-5.
• 27. Long W, Corbet A, Alien A, et al. Retrospective search for bleeding diathesis among premature newborn in￾fants with pulmonary hemorrhage after surfactant treat￾ment. J Pediatr 1992; 120: 45-8.
• 28. Pappin A, Shenker N, Hack M, et al. Extensive intraalveolar pulmoner homorrhage in infants dying af￾ter surfactant therapy. J Pediatr 1994; 124: 621-6.
• 29. Whitsett JA, Hull WM, Luse S. Failure to detect sur￾factant protein-spesific antibodies in sera of premature infants treated with Survanta, a modified bovine surfac￾tant. Pediatrics 1991; 87: 505-10.